# Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

> **NCT06975787** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 90 (estimated)

## Conditions studied

- Lupus Nephritis (LN)

## Interventions

- **DRUG:** Vonsetamig
- **DRUG:** Odronextamab

## Key facts

- **NCT ID:** NCT06975787
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2028-07-23
- **Final completion:** 2028-07-23
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975787, "Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06975787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*